The clinical trial data is clear and sobering: most people regain most of their weight within a year of stopping. Here's why—and what you can do about it.
The promise of GLP-1 medications is significant. The STEP and SURMOUNT clinical trials showed average weight losses of 15–21% of body weight—results that, historically, were only achievable with bariatric surgery. But there's a part of the data that gets less attention in the marketing: what happens when you stop.
The answer, from the STEP-4 withdrawal trial, is stark. And understanding it is essential to making informed decisions about GLP-1 therapy—including whether you're prepared to commit to long-term treatment.
STEP-4 was specifically designed to study what happens when semaglutide is discontinued. In the trial:
Results at 68 weeks total:
This isn't a surprise from a biological standpoint. When you stop a medication that was reducing your appetite and slowing your digestion, your physiology returns to its pre-medication state. The appetite comes back. The food noise returns. Without the pharmacological support, eating behavior reverts.
Understanding why regain happens so quickly and thoroughly helps set realistic expectations and plan accordingly.
The human body evolved to defend its weight. When you lose weight, your body responds with multiple compensatory mechanisms:
GLP-1 medications override most of these adaptations while you're taking them. When you stop, the underlying physiology reasserts itself—and your brain is now fighting with a full biological toolkit to return you to your previous weight.
This is the core of how obesity medicine specialists now frame the regain data: obesity is a chronic, relapsing condition with biological underpinnings—not a lifestyle failure. The obesity medicine field increasingly views GLP-1 therapy the same way cardiologists view antihypertensives: you take the medication because your physiology requires ongoing support, not because you failed to make good choices.
Stopping blood pressure medication doesn't cure hypertension; it removes treatment. Stopping Ozempic doesn't mean you've learned to eat less; it removes pharmacological appetite management.
Weight regain isn't the only thing that reverses when you stop. The STEP-4 data showed that the metabolic improvements seen with semaglutide—reduced waist circumference, improved cardiovascular risk markers, better blood pressure and lipid levels—largely reversed along with the weight regain.
For patients using Ozempic for Type 2 diabetes:
Sometimes stopping GLP-1 treatment is driven by supply shortages, cost, or insurance changes rather than a clinical decision. If you're pausing rather than permanently stopping:
The STEP-4 data doesn't mean all weight loss is inevitably lost—it means that stopping without a plan leads to significant regain. These strategies can help:
The appetite suppression of GLP-1 therapy creates an opportunity. Use it to establish healthier eating patterns—smaller portions, higher protein, less processed food—so that when appetite returns, you have ingrained habits to fall back on. This doesn't eliminate the physiological drivers of regain, but it provides a better baseline.
Rapid weight loss on GLP-1s can include significant lean mass loss alongside fat loss (studies suggest 25–40% of lost weight may be muscle). Resistance training during treatment helps preserve muscle. More muscle means higher resting metabolic rate—which helps counteract the metabolic adaptation that promotes regain.
Rather than stopping abruptly at goal weight, some obesity medicine specialists use a step-down approach: reduce to a lower maintenance dose rather than stopping entirely. Whether this is effective long-term depends on individual response. Some patients can maintain weight at 0.5–1mg/week after losing weight at 2.4mg.
If cost is the reason you're stopping, explore every alternative before discontinuing. Our Cost Calculator can help identify savings programs and lower-cost options (compounded semaglutide, telehealth subscriptions) that might make continuation feasible at lower cost.
Programs like structured meal replacement approaches, very low-calorie diets followed by maintenance protocols, or medical nutrition therapy can help manage the transition. These are not substitutes for GLP-1 therapy, but they provide framework for managing appetite when the pharmacological support is gone.
A meaningful portion of people start GLP-1 therapy with the mental model: "I'll use this to lose the weight, then maintain it on my own." The STEP-4 data suggests this is not how it works for most people. This isn't a character flaw—it's biology.
This has implications for how you think about the financial commitment. Long-term GLP-1 therapy is expensive. At current prices, even at $25–$99/month with assistance programs, it's a significant ongoing cost. Understanding that stopping likely means regaining the weight is an important input into the cost-benefit calculus. Use our Weight Loss Projection to think through the expected outcomes under different scenarios.
If you're considering stopping Ozempic or Wegovy, the conversation with your prescriber should include:
Stopping Ozempic is a legitimate decision—it's your choice, your body, your finances. But going in with accurate expectations about what happens next puts you in a far better position than being surprised by regain.
Ozempic has a half-life of approximately one week, meaning it takes about 5 half-lives (~5 weeks) to be substantially cleared from your system. You'll likely notice appetite returning within 2–3 weeks of your last injection. Blood sugar effects in T2D patients also begin reversing within weeks. Weight regain can begin within weeks of stopping.
There is no clinical requirement to taper Ozempic before stopping—it doesn't cause withdrawal symptoms or rebound phenomena the way some medications do. You can stop after your last dose. However, if you're stopping due to side effects or transitioning to a different medication, your doctor may recommend a different protocol. Discuss your specific situation before stopping.
The metabolic adaptation that occurs with weight loss—reduced resting metabolic rate—does persist, making future weight loss somewhat harder at the same caloric level. This is the "set point defense" in action. However, restarting GLP-1 therapy is effective—there's no indication that previous treatment reduces future responsiveness to the medication.
See a realistic timeline of expected weight loss—and what might happen if you stop—based on clinical trial data and your starting weight.
Weight Loss Projection →Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Never stop a prescription medication without first consulting your healthcare provider. For patients with Type 2 diabetes, stopping Ozempic without a management plan can cause significant blood sugar deterioration. Always work with your prescriber on any medication changes.
Compare Providers
These providers offer online consultations, licensed prescribers, and medication shipped to your door.
GLP-1 specialist. Fast evaluation, compounded semaglutide & tirzepatide, competitive pricing.
Get Started →High patient satisfaction. Compounded semaglutide at lower cost. No in-person visit required.
Get Started →Connects patients with licensed GLP-1 prescribers. Multiple medication options, ongoing support.
Get Started →Compare all GLP-1 providers → • Sponsored links. Medical evaluation required. Results vary. See full provider comparison.